Scientific research services for both medical and non-medical purposes based on transcriptomics, genomic, and proteomic analyses and providing custom consulting services related thereto; Scientific research services for both medical and non-medical purposes, namely analyses and providing custom consulting services based on single-cell omics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data; Scientific research services for analysis of clinical trial data providing custom consulting services related thereto; Scientific research services for identification of therapeutic target and pathways based on single-cell omics, proteomics, genomics, transcriptomics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data, and providing custom consulting services related thereto; Software as service (SaaS) services, namely AI-based identification, collection, curation, and presentation of single-cell data from third party sources; Software as service (SaaS) services, namely AI-based training and generation of translational systems biology models using single-cell data from third party sources, and data from bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data; Software as service (SaaS) services, namely AI-based integration and analysis of single-cell data from third party sources and clinical data, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data; Software as service (SaaS) services, namely AI-based single-cell omics, proteomics, transcriptomics, and genomics; Software as service (SaaS) services, namely identification of therapeutic and cellular pathway target; Software as service (SaaS) services, namely development of novel therapeutic compounds; Software as service (SaaS) services, namely prediction of drug responses and treatment optimization for individual patients based on single-cell omics, proteomics, genomics, transcriptomics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data and patient-specific data; Software as service (SaaS) services, namely patient stratification based on disease progression or recurrence risk identifying those who may benefit from more aggressive treatment or monitoring based on molecular single-cell omics, proteomics, genomics, transcriptomics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data; Software as service (SaaS) services, namely matching patients with clinical trials based on single-cell omics, proteomics, genomics transcriptomics, and bulk modalities of transcriptomics, namely single cell, single nuclei, spatial, bulk, or platforms that provide transcriptomics counts data
Treatment of Materials